Europe’s medical devices industry saw a rise of 7.89% in deal activity during March 2022, when compared with the last 12-month average, led by Angelus Sano Fund, Segulah Medical Acceleration and Waha Capital’s $49m private equity deal with Signifier Medical Technology, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 41 medical devices industry deals worth $251m were announced for the region in March 2022, against the 12-month average of 38 deals.
Of all the deal types, venture financing saw most activity in March 2022 with 20 transactions, representing a 48.8% share for the region.
In second place was M&A with 16 deals, followed by private equity deals with five transactions, respectively capturing a 39.02% and 12.2% share of the overall deal activity for the month.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn terms of value of deals, private equity was the leading category in Europe’s medical devices industry with $106.62m, while venture financing and M&A deals totalled $84.87m and $59.5m, respectively.
Europe medical devices industry deals in March 2022: Top deals
The top five medical devices deals accounted for 60.9% of the overall value during March 2022.
The combined value of the top five medical devices deals stood at $152.92m, against the overall value of $251m recorded for the month.
The top five medical devices industry deals of March 2022 tracked by GlobalData were:
1) Angelus Sano Fund,Segulah Medical Acceleration and Waha Capital $49m private equity deal with Signifier Medical Technology
2) The $36.42m private equity of ITM Isotopen Technologien Munchen by Indigenous Critical Infrastructure Fund Canada (ICIF) and Portland Investment Counsel
3) SourceBio International $24.35m acquisition deal with LDPath
4) The $21.94m acquisition of BioClue and BioStrand by BioKey and ImmunoPrecise Netherlands
5) Heights Capital Ireland $21.2m private equity deal with Renalytix AI
